Annual report
7745.TEDINET S100YHHI
Period2025-04-01 → 2026-03-31
Filed2026-06-23
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥69.3bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥67.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥62.0bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥59.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥9.2bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥8.8bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥9.5bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥9.0bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥8.2bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.6bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥8.7bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥9.1bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.3bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.5bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.9bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥6.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥75.3bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥69.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥72.0bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥69.4bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥59.2bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥25.7bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥26.2bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥49.6bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥42.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥37.8bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥32.6bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥27.0bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.8bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥13.3bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥13.6bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.3bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.0bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥11.0bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥6.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥6.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.2bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥452m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥741m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥216.33 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥235.63 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥192.91 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥201.33 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥216.13 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥235.41 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥192.73 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥201.14 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,806.7 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,560.29 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,370.71 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,183.98 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,167.95 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 65.7% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.8% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.9% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.1% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 19.5% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 15.9% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 2,480 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 2,438 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 2,471 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 2,495 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 2,591 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥3.3bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥3.2bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥2.5bn | 2023-04-01 → 2024-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.5bn | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥35.0bn | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Operating income | ¥2.7bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥2.6bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥2.4bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥2.4bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.6bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥739m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.6bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.4bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.6bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.2bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥2.3bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.3bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥415m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.0bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥37.9bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥38.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥39.3bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥36.7bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥39.6bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥11.2bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥12.5bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥26.7bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥25.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥24.8bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥24.4bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥18.6bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥903m | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.2bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥81.61 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.15 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥46.72 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.15 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥95.62 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥81.53 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.07 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.67 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥15.13 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥95.48 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥55 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥35 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥35 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥25 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥974.61 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥937.8 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥900.94 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥889.74 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥897.51 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 70.5% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 67.2% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.0% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.6% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 46.9% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.5% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.1% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.2% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.9% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 11.1% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 27,845,000 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 27,845,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 27,845,000 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 27,845,000 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 22,601,000 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 743 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 186
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥108m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥75m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥27.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥27.8bn |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | −¥14.4bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.8bn |
| America Measuring Instrumentsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥16m |
| America Measuring Instrumentsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥48m |
| America Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥5.1bn |
| America Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥5.0bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥103m |
| America Measuring Instrumentsreportable segment | segment assets | at 2026-03-31 | ¥4.4bn |
| America Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | −¥345m |
| America Medical And Health Systemreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥29m |
| America Medical And Health Systemreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥81m |
| America Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥11.1bn |
| America Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥11.1bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥8m |
| America Medical And Health Systemreportable segment | segment assets | at 2026-03-31 | ¥6.9bn |
| America Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥168m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥111m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥152m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥9.1bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥5.7bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.4bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2026-03-31 | ¥7.8bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥630m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥361m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥224m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥8.4bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥590m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2026-03-31 | ¥4.3bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥141m |
| Asia And Oceania Semiconductor Related Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥0 |
| Asia And Oceania Semiconductor Related Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥0 |
| Asia And Oceania Semiconductor Related Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥15m |
| Asia And Oceania Semiconductor Related Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥15m |
| Asia And Oceania Semiconductor Related Businessreportable segment | segment assets | at 2026-03-31 | ¥9m |
| Asia And Oceania Semiconductor Related Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥7m |
| Europe Measuring Instrumentsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥43m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥9m |
| Europe Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥618m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥618m |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2026-03-31 | ¥260m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥41m |
| Europe Medical And Health Systemreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥208m |
| Europe Medical And Health Systemreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥114m |
| Europe Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥10.6bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥10.6bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥0 |
| Europe Medical And Health Systemreportable segment | segment assets | at 2026-03-31 | ¥9.5bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥454m |
| Japan Measuring Instrumentsreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥808m |
| Japan Measuring Instrumentsreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥664m |
| Japan Measuring Instrumentsreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥23.9bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥20.2bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥3.7bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2026-03-31 | ¥35.3bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥3.1bn |
| Japan Medical And Health Systemreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥225m |
| Japan Medical And Health Systemreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥259m |
| Japan Medical And Health Systemreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥17.0bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥4.3bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥12.7bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2026-03-31 | ¥7.5bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥3.2bn |
| Japan Semiconductor Related Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥2.3bn |
| Japan Semiconductor Related Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥276m |
| Japan Semiconductor Related Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥11.1bn |
| Japan Semiconductor Related Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥11.1bn |
| Japan Semiconductor Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥11m |
| Japan Semiconductor Related Businessreportable segment | segment assets | at 2026-03-31 | ¥13.7bn |
| Japan Semiconductor Related Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥3.6bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥979m |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥875m |
| Measurement Weighing Instruments Businessesreportable segment | employees | at 2026-03-31 | 1153 pure |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥38.8bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥31.5bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥7.2bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2026-03-31 | ¥47.8bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥3.4bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥824m |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥678m |
| Medical Healthcare Instruments Businessesreportable segment | employees | at 2026-03-31 | 1158 pure |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥47.2bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥26.7bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥20.5bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2026-03-31 | ¥28.2bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥4.0bn |
| Semiconductor Related Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥2.3bn |
| Semiconductor Related Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥276m |
| Semiconductor Related Businessreportable segment | employees | at 2026-03-31 | 115 pure |
| Semiconductor Related Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥11.1bn |
| Semiconductor Related Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥11.1bn |
| Semiconductor Related Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥11m |
| Semiconductor Related Businessreportable segment | segment assets | at 2026-03-31 | ¥13.7bn |
| Semiconductor Related Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥3.6bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥85m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥64m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥28.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥28.4bn |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | −¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥2.1bn |
| America Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥21m |
| America Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥65m |
| America Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥6.1bn |
| America Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.7bn |
| America Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥389m |
| America Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥3.7bn |
| America Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥69m |
| America Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥44m |
| America Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥68m |
| America Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| America Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥10.0bn |
| America Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥2m |
| America Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥5.1bn |
| America Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥472m |
| Asia And Oceania Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥136m |
| Asia And Oceania Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥159m |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥9.1bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥5.6bn |
| Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥7.5bn |
| Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥588m |
| Asia And Oceania Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥47m |
| Asia And Oceania Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥232m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥8.7bn |
| Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥493m |
| Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥8.2bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥3.8bn |
| Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥224m |
| Europe Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥1m |
| Europe Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥2m |
| Europe Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥650m |
| Europe Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥649m |
| Europe Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Europe Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥364m |
| Europe Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥28m |
| Europe Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥44m |
| Europe Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥95m |
| Europe Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥8.8bn |
| Europe Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥8.8bn |
| Europe Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Europe Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥8.3bn |
| Europe Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥193m |
| Japan Measuring Instrumentsreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥809m |
| Japan Measuring Instrumentsreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥642m |
| Japan Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥22.2bn |
| Japan Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥18.7bn |
| Japan Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Japan Measuring Instrumentsreportable segment | segment assets | at 2025-03-31 | ¥32.2bn |
| Japan Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.1bn |
| Japan Medical And Health Systemreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥351m |
| Japan Medical And Health Systemreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥219m |
| Japan Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥17.7bn |
| Japan Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.8bn |
| Japan Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥12.9bn |
| Japan Medical And Health Systemreportable segment | segment assets | at 2025-03-31 | ¥7.8bn |
| Japan Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥3.2bn |
| Japan Semiconductor Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥844m |
| Japan Semiconductor Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥231m |
| Japan Semiconductor Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Japan Semiconductor Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Japan Semiconductor Related Businessreportable segment | segment assets | at 2025-03-31 | ¥14.2bn |
| Japan Semiconductor Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Measurement Weighing Instruments Businessesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥969m |
| Measurement Weighing Instruments Businessesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥869m |
| Measurement Weighing Instruments Businessesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥38.0bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥30.7bn |
| Measurement Weighing Instruments Businessesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥7.3bn |
| Measurement Weighing Instruments Businessesreportable segment | segment assets | at 2025-03-31 | ¥43.8bn |
| Measurement Weighing Instruments Businessesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥2.7bn |
| Medical Healthcare Instruments Businessesreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥488m |
| Medical Healthcare Instruments Businessesreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥616m |
| Medical Healthcare Instruments Businessesreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥45.2bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥24.1bn |
| Medical Healthcare Instruments Businessesreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥21.1bn |
| Medical Healthcare Instruments Businessesreportable segment | segment assets | at 2025-03-31 | ¥24.9bn |
| Medical Healthcare Instruments Businessesreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.1bn |
| Semiconductor Related Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥844m |
| Semiconductor Related Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥231m |
| Semiconductor Related Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Semiconductor Related Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.3bn |
| Semiconductor Related Businessreportable segment | segment assets | at 2025-03-31 | ¥14.2bn |
| Semiconductor Related Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥4.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,995
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 3997000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.1442 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 2173000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0784 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 1128000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0407 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 1113000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0402 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 701000 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0253 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 679000 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0245 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 652000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0235 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 606000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0219 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 595000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0215 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 564000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0204 | |
| Number of shares held | CurrentYearInstant | 12212000 | |
| Shareholding ratio | CurrentYearInstant | 0.4405 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 120100 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 27660000 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 276600 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 65108 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 27845208 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 276600 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 120100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 120100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0043 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 120100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 120100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0043 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 693000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 25.00 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 831000000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 30.00 | |
| Number of male directors and other officers | FilingDateInstant | 9 | |
| Number of female directors and other officers | FilingDateInstant | 1 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.100 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02344-000MorishimaYasunobuMember | 247000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02344-000HaoZhangMember | 14000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E02344-000TakahashiKojiMember | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |